| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Tubulin; impurity of taxol
Microtubules/tubulin (microtubule stabilizing agent); targets involved in cancer cell cytotoxicity. |
|---|---|
| ln Vitro |
Activity-guided, chromatographic fractionation for a polar extract of Taxus wallichiana Zucc. (originally identified as Cephalotaxus mannii Hook.) resulted in the isolation of three new KB cytotoxic taxane derivatives. Nmr and ms spectral analyses permitted their characterization as 19-hydroxybaccatin III (3), 10-deacetylcephalomannine (4), and 10-deacetyltaxol (5). The latter two compounds, which are also active against PS leukemia in vivo, were observed to be especially labile, each forming equilibrium mixtures with their cytotoxic C-7 epimers (9, 10)[1].
In vitro, 10-deacetyltaxol exhibits cytotoxic effects against various cancer cell lines, including human glioblastoma multiforme and neuroblastoma cell lines. The order of potency after 1-hour exposure was taxol > 10-deacetyltaxol > cephalomannine. Cytotoxicity is concentration-dependent, with neuroblastoma SK-N-FI being the most resistant cell line. 10-Deacetyltaxol is less toxic than taxol but remains within a therapeutic range. |
| ln Vivo |
In vivo, 10-deacetyltaxol is active against PS leukemia. It has been shown to have antitumor activity in murine models. The compound is less toxic than paclitaxel in vivo but retains therapeutic efficacy. However, detailed dose-response and pharmacokinetic data in animal models are limited.
|
| Enzyme Assay |
No specific cell-free enzyme assay protocol is detailed for 10-deacetyltaxol. For taxane compounds, typical cell-free assays include tubulin polymerization assays: purified tubulin is incubated with the compound, and microtubule assembly is monitored turbidimetrically at 340 nm. IC50 values for tubulin polymerization inhibition or promotion are calculated from dose-response curves.
|
| Cell Assay |
The cytotoxic effects of taxol, 10-deacetyltaxol, and cephalomannine at concentrations of 0.1 mug/ml to 10.0 mug/ml for one and 24 hours exposure were determined in two human glioblastoma multiforme and two neuroblastoma cell lines using the MTT method. The neuroblastoma cell lines were established from previously treated patients, while the glioblastomas were from untreated patients. There was a proportionate concentration-toxicity relationship for all four cell lines. The neuroblastoma SK-N-FI was consistently the most resistant to all three drugs. The order of potency after a one hour exposure was taxol, 10-deacetyltaxol and cephalomannine. Cephalomannine contained 1.5% taxol impurity and 10-deacetyltaxol, 4.5% taxol hence the contribution of taxol to these substances' toxic effects was minimal. We conclude that tumors of the central and peripheral nervous system are sensitive to 10-deacetyltaxol and cephalomannine and these drugs are less toxic than taxol but remain within a therapeutic range[3].
Cytotoxicity is assessed in cancer cell lines (e.g., glioblastoma, neuroblastoma, KB cells) using the MTT method. Cells are seeded in 96-well plates, treated with serial dilutions of 10-deacetyltaxol (0.1-10.0 µg/mL) for 1 or 24 hours, and cell viability is measured. IC50 values are calculated from concentration-toxicity curves. |
| Animal Protocol |
In vivo efficacy is evaluated in murine tumor models (e.g., PS leukemia, xenograft models). 10-Deacetyltaxol is administered via intravenous or intraperitoneal injection. Endpoints include tumor volume reduction, survival extension, and toxicity assessment. Activity-guided fractionation from Taxus wallichiana led to isolation of 10-deacetyltaxol along with other active taxanes.
|
| ADME/Pharmacokinetics |
Molecular weight: 811.87; molecular formula: C45H49NO13. Melting point: 182-184°C. Boiling point: 959.5±65.0°C (predicted). Solubility: typical for taxane compounds in organic solvents. Storage: typical for taxane compounds (desiccated, protected from light).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. 10-Deacetyltaxol is reported to be less toxic than paclitaxel. However, standard toxicological studies (acute/chronic toxicity, genotoxicity, cardiotoxicity) would be required for drug development.
|
| References | |
| Additional Infomation |
Deacetylated paclitaxel is a taxane diterpenoid compound. It has been reported to exist in yew (Taxus cuspidata), hazel (Corylus avellana), and other organisms with relevant data. 10-Deacetylated paclitaxel is an analog of paclitaxel and possesses antitumor activity. It binds to and stabilizes microtubules, thereby inhibiting microtubule depolymerization, ultimately leading to cell cycle arrest at the G2/M phase and inducing apoptosis.
10-Deacetyltaxol is a research-grade compound, not approved for therapeutic use. It is primarily used as a reference standard, impurity standard, and for pharmacological research in cancer biology. No clinical trials have been reported. It is a natural taxane diterpenoid found in yew (Taxus cuspidata), hazel (Corylus avellana), and other organisms. |
| Molecular Formula |
C₄₅H₄₉NO₁₃
|
|---|---|
| Molecular Weight |
811.87
|
| Exact Mass |
811.32
|
| CAS # |
78432-77-6
|
| Related CAS # |
78432-77-6
|
| PubChem CID |
155831
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
959.5±65.0 °C at 760 mmHg
|
| Melting Point |
182-184ºC
|
| Flash Point |
534.1±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
6.74
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
59
|
| Complexity |
1680
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O1C([H])([H])[C@@]2([C@@]1([H])C([H])([H])[C@]([H])([C@@]1(C([H])([H])[H])C([C@]([H])(C3=C(C([H])([H])[H])[C@]([H])(C([H])([H])[C@](C3(C([H])([H])[H])C([H])([H])[H])([C@]([H])([C@]21[H])OC(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)O[H])OC([C@@]([H])([C@]([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)O[H])=O)O[H])=O)O[H])OC(C([H])([H])[H])=O
|
| InChi Key |
TYLVGQKNNUHXIP-MHHARFCSSA-N
|
| InChi Code |
InChI=1S/C45H49NO13/c1-24-29(57-41(54)35(50)33(26-15-9-6-10-16-26)46-39(52)27-17-11-7-12-18-27)22-45(55)38(58-40(53)28-19-13-8-14-20-28)36-43(5,37(51)34(49)32(24)42(45,3)4)30(48)21-31-44(36,23-56-31)59-25(2)47/h6-20,29-31,33-36,38,48-50,55H,21-23H2,1-5H3,(H,46,52)/t29-,30-,31+,33-,34+,35+,36-,38-,43+,44-,45+/m0/s1
|
| Chemical Name |
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
|
| Synonyms |
10-Deacetylpaclitaxel; 10-Deacetyltaxol; 10-Desacetyl Paclitaxel; 10-Deacetylpaclitaxel; 10-deacetyl-paclitaxel; 10-Desacetyltaxol; B77R96LJLK; 10-Deacetyltaxol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 27~125 mg/mL (33.3~154 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2317 mL | 6.1586 mL | 12.3172 mL | |
| 5 mM | 0.2463 mL | 1.2317 mL | 2.4634 mL | |
| 10 mM | 0.1232 mL | 0.6159 mL | 1.2317 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
